Systemic exposure of floxuridine after hepatic arterial infusion pump chemotherapy with floxuridine in patients with resected colorectal liver metastases

Background: Floxuridine's high hepatic extraction ratio and short elimination half-life allows maximum liver exposure with minimal systemic side-effects.This study attempts to quantify the systemic exposure of floxuridine.Methods: Patients undergoing continuous hepatic arterial infusion pump (HAIP) floxuridine after resection of colorectal liver metastases (CRLM) in two centres underwent six cycles of floxuridine at start dose 0.12 mg/kg/ day.No concomitant systemic chemotherapy was administered.Peripheral venous blood samples were drawn during the first two cycles: pre-dose (only in the second cycle), 30 min, 1 h, 2 h, 7 h, and 15 days after floxuridine infusion.Foxuridine concentration in the residual pump reservoir was measured on day 15 of both cycles.A floxuridine assay with a lower boundary of detection of 0.250 ng/mL was developed.Results: 265 blood samples were collected in the 25 patient included in this study.Floxuridine was mostly measurable at day 7 and day 15 (86 % and 88 % of patients respectively).The median dose corrected concentrations were 0.607 ng/mL [IQR: 0.472-0.747]for cycle 1 day 7, 0.579 ng/mL [IQR: 0.470-0.693]for cycle 1 day 15, 0.646 ng/mL [IQR: 0.463-0.8546]for cycle 2 day 7, and 0.534 ng/mL [IQR: 0.4257-0.7075]for cycle 2 day 15.One patient had remarkably high floxuridine concentrations reaching up to 44 ng/mL during the second cycle, without a clear explanation.The floxuridine concentration in the pump decreased by 14.7 % (range 0.5 %-37.8 %) over a period of 15 days (n = 18).Conclusion: Overall, negligible systemic concentrations of floxuridine were detected.However, remarkably increased levels were detected in one patient.Floxuridine concentration in the pump decreases over time.